ESC 365 - Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

HFA Premium Access

Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

Session: Poster Session 2 - Cardiovascular Disease in Special Populations

Topic: Cardio-Oncology

Speaker: Miss N. Bouwer (Dordrecht, NL)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Miss Nathalie Bouwer

Albert Schweitzer Hospital, Dordrecht (Netherlands (The))

0 follower

13 more presentations in this session

Trastuzumab associated cardiotoxicity in breast cancer patients: a report after 4 years of follow up at a specialized centre

Speaker: Doctor M. Tettamanti (Buenos Aires, AR)

Body mass index and resting heart rate in unselected prospectively enrolled cancer patients

Speaker: Doctor S. Hadzibegovic (Berlin, DE)

Echocardiographic assessment in cancer patients

Speaker: Doctor A. Lena (Berlin, DE)

Troponin T, NT-proBNP and CRP: prognostic markers of mortality in cancer patients

Speaker: Ms L. Lueck (Berlin, DE)

Biomarkers and imaging modalities for the diagnosis of cardiotoxicity after chemotherapy; data from the greek multicenter cardio-oncology registry

Speaker: Doctor A. Ntalianis (Athens, GR)

Access the full session

Poster Session 2 - Cardiovascular Disease in Special Populations

Speakers: Miss N. Bouwer, Doctor M. Tettamanti, Doctor S. Hadzibegovic, Doctor A. Lena, Ms L. Lueck...

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources